Connect with us
DAPA Banner

Business

At Close of Business podcast March 31 2026

Published

on

At Close of Business podcast March 31 2026
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Eli Lilly to acquire Centessa and sleep disorder drugs

Published

on

Biotech takeover targets: Here’s what you need to know

Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday.

Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake during the day. The drugs may also be used to treat other neurological conditions that are accompanied by drowsiness, such as Alzheimer’s disease and depression, and possibly even more broadly.

Other possibilities include another severe sleep disorder called idiosyncratic hypersomnia, as well as other conditions where people experience sleepiness or executive function problems during the day and poor sleep at night, Lilly CEO Dave Ricks said in an interview with CNBC.

“We see a broader potential for this pathway, maybe a little bit of analogy to GLP-1, in a way that, you know, sleep and wakefulness are like core to our functioning, and when your sleep is disturbed or your wakefulness is disturbed, it causes a lot of other problems,” Ricks said. “So I think you can count on Lilly exploring broad use for [the orexins] and this new pathway, and we’re pretty excited about it.”

Advertisement

Under the terms of the deal, Lilly will pay $38 a share up front, or $6.3 billion for Centessa, a 38% premium to Monday’s closing price. If Centessa’s drugs win approval by the U.S. Food and Drug Administration by certain deadlines, Lilly will pay up to another $1.5 billion.

The transaction is expected to close in the third quarter, pending regulatory approval.

Shares of Lilly rose roughly 3% Tuesday, while Centessa’s stock surged 45%.

Orexin agonists used to treat narcolepsy and another severe sleep condition, called idiopathic hypersomnia, could amount to a $15 billion to $20 billion market if even about one-quarter of patients seek treatment, according to an estimate from Oppenheimer analyst Kostas Biliouris. Sales could go even higher if the drugs are used more broadly.

Advertisement

Centessa won’t be the first to market with its orexin agonist. A rival drug from Takeda is under review with the FDA and could be approved later this year.

Biliouris said he doesn’t expect Centessa’s drug to be approved until 2028, but he sees signs from mid-stage trial data that Centessa’s treatment could become the best in class.

Lilly, for its part, is a longtime leader in neuroscience. The company’s antidepressant Prozac catapulted Lilly to the top ranks of the pharmaceutical industry after it was approved in 1987.

More recently, Lilly introduced a drug called Kisunla for the early stages of Alzheimer’s disease with another trial on the horizon to see if the treatment can prevent the memory-robbing disease.

Advertisement

Lilly has been vocal about its intention to use the cash coming from its best-selling obesity and diabetes drugs Zepbound and Mounjaro to place more bets. Already this year, Lilly announced its intention to acquire cell-therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences.

Of the Centessa deal, Ricks said, “It’s the kind of thing we should be doing to really affect millions and millions of people, potentially, who suffer from neuroscience conditions like wakefulness and sleep.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

WA, federal govt to sign enviro deal by year end, minister hopes

Published

on

WA, federal govt to sign enviro deal by year end, minister hopes

The state aims to enter a bilateral environmental regulatory agreement with the Commonwealth by late 2026, pushing out the timeframe previously flagged by Premier Roger Cook.

Continue Reading

Business

Labor Department's proposal is a 'huge step' for your 401(k), BlackRock's Nefouse says

Published

on

A proposed Department of Labor rule could significantly expand what Americans are able to hold inside their retirement accounts, potentially opening the door to assets like cryptocurrency, real estate and private markets.

BlackRock Global Head of Retirement Solutions Nick Nefouse described the rule as “a huge step forward for the 401(k) market” while discussing what the change could mean for everyday investors during his appearance on “Varney & Co.” Tuesday.

“The proposed regulation explains the steps that managers of 401(k) plans should take when considering alternative assets as a component in their investment lineups and establishes a set of process-based safe harbors for plan fiduciaries to use when selecting designated investment alternatives,” the Labor Department said in a press release on March 30.

Rather than endorsing specific investments, Nefouse suggested that the proposal is focused on creating a structured process for plan providers to follow when evaluating alternative assets.

Advertisement

AMERICANS TAP RETIREMENT FUNDS AT RECORD RATES AS MOUNTING FINANCIAL STRESS TAKES TOLL

“What the rule is trying to do… is establish a process, not necessarily say which asset classes are good or bad,” Nefouse said.

The shift could narrow a long-standing gap between retirement systems. While large institutional-style plans already have access to a wider range of investments, many workers in traditional 401(k) plans do not.
LARRY FINK CALLS FOR SOCIAL SECURITY REFORM, SAYS INVESTING A PORTION OF FUNDS COULD STRENGTHEN THE PROGRAM

“Think of regular people. About 25% of the population are in defined benefit plans. About 80% are in defined contribution plans,” Nefouse said. 

Advertisement

“What we’re trying to do is level the playing fields, and so many Americans are relying on 401(k) plans,” he added.

The change could broaden access to investment options that have traditionally been limited to institutional retirement plans.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Advertisement
Continue Reading

Business

Oil nears highest price since start of Iran war

Published

on

The US-Israel Iran war has halted almost all traffic in a key waterway and the price Brent crude has surged.

Continue Reading

Business

(VIDEO) Tiger Woods Had Hydrocodone Pills in Pocket During Florida DUI Rollover Crash, Affidavit Reveals

Published

on

Golfing superstar Tiger Woods spent his second full day recovering from a car crash at Los Angeles Cedars-Sinai hospital which is known for treating wealthy celebrities

Golf legend Tiger Woods was found with two loose hydrocodone pills — a prescription opioid — in his left pants pocket after a single-vehicle rollover crash that led to his arrest on suspicion of driving under the influence last Friday, according to a probable cause affidavit released Tuesday by Martin County authorities.

Golfing superstar Tiger Woods spent his second full day recovering from a car crash at Los Angeles Cedars-Sinai hospital which is known for treating wealthy celebrities
GETTY IMAGES NORTH AMERICA / ANDY LYONS

The new details, first reported by TMZ Sports and confirmed across multiple outlets, paint a fuller picture of the March 27 incident on a residential road in the affluent Jupiter Island community. Woods, 50, told deputies he was distracted by his cellphone and changing the radio station moments before his luxury Land Rover struck the rear of a work truck and flipped onto its side. No one was seriously injured, but the crash has reignited questions about the 15-time major champion’s ongoing battles with pain management, prescription medications and road safety.

Deputies described Woods as profusely sweating despite cool air in the vehicle, moving in a “lethargic and slow” manner, and showing “severe signs of impairment.” When he removed his sunglasses, officers noted his eyes were “bloodshot and glassy” with “extremely dilated” pupils. A breathalyzer test registered 0.00 for alcohol, but Woods refused a urine test under Florida’s strengthened implied consent law for suspected drug impairment, leading to an additional charge.

During a search incident to arrest, deputies discovered two white pills marked “M367” in Woods’ pocket. The imprint identified them as hydrocodone, an opioid commonly prescribed for severe or chronic pain. Woods acknowledged taking “a few” prescription medications earlier that morning when asked by investigators. The pills were seized and entered into evidence.

Advertisement

The affidavit adds to the narrative of a golfer whose body has endured years of punishing physical tolls from elite competition and multiple surgeries, including multiple back operations and a 2021 car crash in California that left him with severe leg injuries. Woods has been open in the past about relying on pain medication during recovery periods, but the presence of loose opioids during a driving incident has drawn sharp scrutiny.

Martin County Sheriff John Budensiek said at a news conference last week that investigators believed Woods was impaired by “some type of medication or drug” rather than alcohol. Woods was booked on misdemeanor charges of DUI with property damage and refusal to submit to a lawful test. He was released from jail overnight Friday after posting bond and has not yet entered a plea.

The crash occurred around 2 p.m. as Woods reportedly attempted to pass a pressure cleaner truck on a road with a 30 mph speed limit. He crawled out of the overturned vehicle through a window and was seen on his phone near the wreckage. Photos from the scene showed the Land Rover resting on its side with visible damage.

This marks Woods’ second high-profile DUI-related incident. In 2017, he was arrested in Florida after being found asleep at the wheel of his Mercedes. Toxicology reports at the time revealed five substances in his system, including the opioid hydrocodone (Vicodin), hydromorphone (Dilaudid), Xanax, Ambien and THC. Woods later pleaded guilty to reckless driving and completed a program addressing his issues with prescription medications.

Advertisement

Tuesday’s affidavit has prompted fresh discussion about prescription opioid use among athletes managing chronic pain. Hydrocodone is a Schedule II controlled substance with high potential for dependence. Medical experts note that while it can be legitimately prescribed, combining it with other medications or using it while driving can significantly impair judgment, reaction time and coordination.

Woods has been attempting a cautious comeback in 2026 after years of limited competitive play due to injuries. He participated in the TGL Finals earlier in the week, a tech-infused golf league event, and had expressed hope of competing at the Masters Tournament, which begins April 9 in Augusta, Georgia. His representatives have not commented publicly on the latest developments or his plans for the storied event, where he has won five green jackets.

PGA Tour officials and fellow players have offered measured responses, emphasizing support for Woods’ health while noting the seriousness of impaired driving. Some teammates in the TGL expressed concern over what one called “disturbing” recent events.

The incident also revives memories of Woods’ 2021 rollover crash in Rancho Palos Verdes, California, where his SUV veered off a winding road at high speed. He suffered compound fractures in his right leg and underwent extensive rehabilitation. An empty pill bottle was reportedly found in that vehicle, though no charges were filed related to impairment.

Advertisement

Legal analysts say the current case could hinge on field sobriety test performance, the deputy’s observations of impairment, the refused urine test and any eventual toxicology results if pursued. Under Florida law, refusal to submit to testing after a DUI arrest can lead to automatic license suspension and may be used as evidence in court.

Woods owns multiple properties in the Jupiter area, including a waterfront estate, and has deep ties to South Florida’s golf community. He has largely kept a low profile off the course in recent years, focusing on his children, business ventures such as his golf course design firm and the TGL league he co-founded with Rory McIlroy.

Public reaction on social media has been swift and divided. Some fans expressed disappointment and concern for Woods’ well-being, while others highlighted the potential dangers of driving while impaired by any substance. The story dominated sports headlines Tuesday, with the new affidavit details amplifying coverage of the Friday crash.

As of Tuesday afternoon, no court date had been set. Woods remains eligible to travel and compete pending resolution of the charges, though any conviction could carry consequences for his driving privileges and public image.

Advertisement

The golf world will watch closely how Woods navigates this latest chapter. His resilience through physical adversity has been well-documented, but repeated incidents involving driving and medications raise questions about long-term management of his health and lifestyle.

Martin County authorities have not released bodycam or dashcam footage, citing the ongoing investigation. The second driver involved in the crash was not injured and cooperated with investigators.

For a figure who transcended golf to become one of the most recognizable athletes globally, Tuesday’s revelations add another complex layer to a career marked by triumph, scandal, injury and remarkable comebacks. Whether this proves a minor legal hurdle or a more significant turning point remains to be seen as the legal process unfolds.

Woods’ team has historically emphasized privacy around medical matters. In past statements, he has credited surgery, physical therapy and mental focus for his recoveries while acknowledging the cumulative wear on his body from decades at the highest level of professional golf.

Advertisement

As spring arrives and the golf season intensifies toward the Masters, the focus for many will shift from Woods’ past glories to his present challenges — both on and off the course. Supporters hope for transparency, accountability and continued progress in addressing any underlying issues with pain and medication.

Continue Reading

Business

Apartments planned above resort’s iconic former Woolworths store

Published

on

Apartments planned above resort’s iconic former Woolworths store


Amendments made to project at Art Deco landmark

Continue Reading

Business

Perth family law firm Paterson & Dowding wins injunction to protect stolen data

Published

on

Perth family law firm Paterson & Dowding wins injunction to protect stolen data

A boutique Perth family law firm has been granted an injunction over data stolen during a recent cyber attack, preventing it from being accessed and shared by Australian outlets or companies.

Continue Reading

Business

US petrol price tops $4 for first time since 2022

Published

on

US petrol price tops $4 for first time since 2022

The Iran war continues to push up prices at the pump for US motorists.

Continue Reading

Business

Novo Nordisk launches Wegovy subscription for GLP-1 obesity drugs

Published

on

Wegovy semaglutide tablets.

Michael Siluk | Universal Images Group | Getty Images

Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, “predictable” monthly prices. 

Advertisement

Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year on the pill, relative to paying for their individual dose each month, according to a Novo release. 

Patients can expect to pay flat monthly prices, even if they move to different doses, the company said. The subscription program will be available starting Tuesday on several of Novo’s telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame and Hims & Hers, with more expected to be added soon. 

The first-of-its-kind offering is “an opportunity to help patients not only start but stay on therapy and help them manage the ups and downs of some of the pricing considerations,” regardless if they are starting treatment or are currently taking the drug, said Ed Cinca, Novo’s head of marketing and patient solutions. 

Inability to stay on GLP-1s is a longstanding issue due to factors such as difficulty accessing the drugs and gastrointestinal side effects, with one 2025 study estimating that around 65% of patients with obesity stop treatment within a year. 

Advertisement

Wegovy subscription prices and estimated savings

Injection subscription plans (0.25, 0.5, 1.7 and 2.4 milligram doses)

  • 3-month: $329 per month, savings of $240 per year
  • 6-month: $299 per month, savings of $600 per year
  • 12-month: $249 per month, savings of $1,200 per year

Pill subscription plans (9 and 25 milligram doses) 

  • 3-month: $289 per month, savings of $120 per year
  • 6-month: $269 per month, savings of $360 per year
  • 12-month: $249 per month, savings of $600 per year

The new program also comes as Novo’s pill, which has seen explosive uptake since its U.S. launch in January, is set to face fresh competition from an upcoming oral GLP-1 from chief rival Eli Lilly later this year. Lilly is currently the dominant player in the branded GLP-1 market in the U.S., with an estimated 60% share, while Novo has about 39%.

The Wegovy pill has largely been reaching people who didn’t previously take GLP-1 injections, making it crucial for Novo to capture as many new patients as it can before a competitor arrives. 

As Novo Nordisk’s subscription plans launch, cash-paying patients can still pay $149 per month for the lower doses of the pill, which are 1.5 and 4 milligrams. But starting in August, the 4-milligram dose will cost $199 per month. Meanwhile, the recently approved 7.2-milligram dose of Wegovy will be added to the subscription program at a later date. 

Advertisement

Cinca emphasized that patients can opt out of the subscription while it’s active if they no longer wish to enroll.

“We want to help patients identify a path that can help them feel comfortable about treating [obesity] in the long term,” he added.

Cinca said Novo is not yet offering the program on its NovoCare direct-to-consumer pharmacy, but added that there’s “an opportunity to evaluate how this goes and then build it out” through that platform over time. 

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading

Business

Bulls to return after March massacre? Elara sees limited downside for Nifty after 11% crash amid Iran-US war

Published

on

The raging war in the oil-rich Middle East has rattled stock markets across the globe, with Dalal Street being no exception. After crashing more than 11% in March, Elara Securities said that historical patterns suggest limited downside for the benchmark index Nifty.

The domestic brokerage cited data from the timeframes of seven major geopolitical conflicts in the past 25 years – Iraq war (2003), the Lebanon war (2006), the Libyan Civil War (2011), Russia–Ukraine (2022), Israel–Hamas war (2023), Iran–Israel conflict (2025), and the ongoing US–Iran escalation. It said that Nifty’s drawdown during the onset of conflicts has usually been capped at approximately 10%. Hence, historical patterns suggest limited downside for the benchmark index now, after the 11% crash in March.

“Importantly, once early signs of normalisation emerge, markets tend to recover swiftly,” Elara said. However, it noted that the key exception to this historical pattern was in calendar years 2011-2014 when Brent sustained above $100 per barrel, leading to a prolonged sideways market without meaningful highs. The eventual decline in oil prices acted as the trigger for a strong Nifty upcycle, it added.

Also read: Sammaan Capital becomes IHC Group co, receives Rs 5,652 cr in first tranche of stake sale

Advertisement

Nifty’s valuation below the long-term trend signals a potential rebound

Elara assessed the one-year forward P/E relative to its rolling 10-year average and concluded the Nifty is trading 7% below its 10-year average, placing it in a historical “bounce zone”. “Outside of extreme disruptions like COVID-19, this level usually acted as a floor for valuation. Even during the Russia–Ukraine conflict, despite Brent sustaining above USD 100/bbl, Nifty multiples bounced back from 10-year rolling averages,” it said.

“The recent TACO and Iran allowing ‘nonhostile ships’ to transit the Strait of Hormuz, along with crude oil prices dropping below USD 100/bbl, have reduced immediate energy supply risks. With our base case assuming gradual de-escalation, the current valuation provides a favourable entry point, with limited downside. We pick 20 value plays which offer a good risk-reward opportunity with healthy fundamentals in the current scenario of extreme correction,” the brokerage added.

Elara’s top pics

Auto and power remain Elara’s preferred bets, which added that large-cap auto stocks like Maruti Suzuki and Royal Enfield-maker Eicher Motors have corrected sharply since the onset of the US-Iran conflict. While near-term concerns persist around input cost pressures from elevated commodity prices and potential demand moderation in the event of a prolonged conflict triggering an inflation shock for consumers, underlying retail data remains robust and encouraging, it further said.
The domestic brokerage added that Vahan retail registrations so far show strong double-digit growth, and this momentum is expected to receive further tailwinds from the Eighth Pay Commission awards, slated for announcement early next year.Within the power sector, 18 out of the 19 utility stocks under the brokerage’s coverage have outperformed the Nifty 50 in current drawdown, which the firm said underscores the sector’s relative resilience. “The escalating conflict is expected to accelerate India’s electrification cycle, while surging data centre capex is driving incremental power demand. This positive backdrop is further supported by the likely passage of the New Electricity Amendment Bill, which will unlock structural reforms in the sector. Consequently, power generation, transmission, distribution, and data centre-linked plays are emerging not merely as defensive anchors but as clear structural beneficiaries in the medium to long term. NTPC, NLC India, and ACME Solar remain our highest conviction picks within the space,” it added.

Also read: FY26 IPO market a disaster as investors lose money in 2 out of 3 issues. Will next year be better?

Where is the value currently?

In its report, Elara listed out several stocks emerging with better risk-reward dynamics where fundamentals remain intact, and valuation is either trading below the five-year median, and in some cases even below the Russia–Ukraine crisis lows.

Advertisement

These include HDFC Bank, Maruti Suzuki, Eicher Motors, Infosys, LTI Mindtree, L&T, Godrej Properties, NTPC, NLC India, ACME Solar and Eternal.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Continue Reading

Trending

Copyright © 2025